Cell Growth & Differentiation, Vol 7, Issue 12 1783-1791, Copyright © 1996 by American Association of Cancer Research

ARTICLES

Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid receptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis

S Nagpal, SM Thacher, S Patel, S Friant, M Malhotra, J Shafer, G Krasinski, AT Asano, M Teng, M Duvic and RA Chandraratna
Department of Biology, Allergan Inc., Irvine, California 92713, USA.

Retinoids down-regulate the expression of metalloproteinases, cytokines, and other genes involved in cell proliferation and inflammation. Tazarotene (AGN 190168), a retinoic acid receptor (RAR)-specific retinoid, is effective in the treatment of psoriasis, a hyperproliferative and inflammatory skin disease. Because negative regulation of genes appears to be important in the antiproliferative and antiinflammatory action of retinoids, we studied the down-regulation of genes in skin raft cultures by this antipsoriatic retinoid. By subtraction hybridization, we found that migration inhibitory factor-related protein (MRP-8) and skin-derived anti-leukoproteinase (SKALP) are down-regulated by AGN 190168. MRP-8 and SKALP are overexpressed in psoriatic lesions as compared to the normal epidermis, and they are markers of hyperproliferative keratinocyte differentiation. We also show that MRP-8 expression is retinoid inhibitable in cultured keratinocytes induced to differentiate with 10% serum or IFN-gamma, and that MRP-8 is inhibited by RAR but not by retinoid X receptor-specific retinoids in a dose-dependent manner. Finally, MRP-8, SKALP, and the previously characterized differentiation marker, transglutaminase I, are all down-regulated in vivo in psoriatic lesions after treatment with AGN 190168 in comparison to placebo. Taken together, these data suggest that these markers may be down-regulated by tazarotene in psoriasis through direct action on keratinocyte gene expression rather than by an overall tazarotene effect on lesional therapeutic status.

This article has been cited by other articles:

				G. Tjabringa, M. Bergers, D. van Rens, R. de Boer, E. Lamme, and J. Schalkwijk Development and Validation of Human Psoriatic Skin Equivalents Am. J. Pathol., September 1, 2008; 173(3): 815 - 823. [Abstract] [Full Text] [PDF]

				H.Y. Sroussi, J. Berline, P. Dazin, P. Green, and J.M. Palefsky S100A8 Triggers Oxidation-sensitive Repulsion of Neutrophils J. Dent. Res., September 1, 2006; 85(9): 829 - 833. [Abstract] [Full Text] [PDF]

				S. Bershad, G. K. Singer, J. E. Parente, M.-H. Tan, D. W. Sherer, A. N. Persaud, and M. Lebwohl Successful Treatment of Acne Vulgaris Using a New Method: Results of a Randomized Vehicle-Controlled Trial of Short-Contact Therapy With 0.1% Tazarotene Gel Arch Dermatol, April 1, 2002; 138(4): 481 - 489. [Abstract] [Full Text] [PDF]

				M. Duvic, B. Helekar, C. Schulz, M. Cho, D. DiSepio, C. Hager, D. DiMao, P. Hazarika, B. Jackson, J. Breuer-McHam, et al. Expression of a Retinoid-inducible Tumor Suppressor, Tazarotene-inducible Gene-3, Is Decreased in Psoriasis and Skin Cancer Clin. Cancer Res., August 1, 2000; 6(8): 3249 - 3259. [Abstract] [Full Text]

				S. M. Thacher, S. Nagpal, E. S. Klein, T. Arefieg, G. Krasinski, D. DiSepio, C. Agarwal, A. Johnson, R. L. Eckert, and R. A. S. Chandraratna Cell Type and Gene-specific Activity of the Retinoid Inverse Agonist AGN 193109: Divergent Effects from Agonist at Retinoic Acid Receptor {{gamma}} in Human Keratinocytes Cell Growth Differ., April 1, 1999; 10(4): 255 - 262. [Abstract] [Full Text]

				D. DiSepio, M. Malhotra, R. A. S. Chandraratna, and S. Nagpal Retinoic Acid Receptor-Nuclear Factor-Interleukin 6 Antagonism. A NOVEL MECHANISM OF RETINOID-DEPENDENT INHIBITION OF A KERATINOCYTE HYPERPROLIFERATIVE DIFFERENTIATION MARKER J. Biol. Chem., October 10, 1997; 272(41): 25555 - 25559. [Abstract] [Full Text] [PDF]

				S. M. Thacher, A. M. Standeven, J. Athanikar, S. Kopper, O. Castilleja, M. Escobar, R. L. Beard, and R. A. S. Chandraratna Receptor Specificity of Retinoid-Induced Epidermal Hyperplasia: Effect of RXR-Selective Agonists and Correlation with Topical Irritation J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 528 - 534. [Abstract] [Full Text]

				I. S. Thorey, J. Roth, J. Regenbogen, J.-P. Halle, M. Bittner, T. Vogl, S. Kaesler, P. Bugnon, B. Reitmaier, S. Durka, et al. The Ca2+-binding Proteins S100A8 and S100A9 Are Encoded by Novel Injury-regulated Genes J. Biol. Chem., September 14, 2001; 276(38): 35818 - 35825. [Abstract] [Full Text] [PDF]